Cambrex Corp. (NYSE:CBM)’s share price rose 2.8% during trading on Wednesday . The company traded as high as $51.85 and last traded at $51.10, with a volume of 339,488 shares. The stock had previously closed at $49.73.

Separately, Zacks Investment Research lowered shares of Cambrex Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th.

The firm has a market cap of $1.71 billion and a P/E ratio of 27.38. The company’s 50-day moving average is $52.72 and its 200-day moving average is $45.29.

Cambrex Corp. (NYSE:CBM) last announced its earnings results on Thursday, July 28th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.09. The business had revenue of $118.22 million for the quarter, compared to the consensus estimate of $114.85 million. During the same quarter last year, the firm posted $0.63 earnings per share. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts forecast that Cambrex Corp. will post $2.56 earnings per share for the current year.

In related news, CEO Steven M. Klosk sold 16,430 shares of the business’s stock in a transaction that occurred on Thursday, May 5th. The shares were sold at an average price of $49.13, for a total transaction of $807,205.90. Following the completion of the sale, the chief executive officer now directly owns 136,828 shares in the company, valued at $6,722,359.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director William B. Korb sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 3rd. The shares were sold at an average price of $49.09, for a total transaction of $392,720.00. Following the sale, the director now owns 32,562 shares of the company’s stock, valued at $1,598,468.58. The disclosure for this sale can be found here.

A number of hedge funds have made changes to their positions in CBM. Pear Tree Advisors Inc. acquired a new stake in shares of Cambrex Corp. during the fourth quarter valued at about $1,008,000. GSA Capital Partners LLP raised its stake in shares of Cambrex Corp. by 33.2% in the fourth quarter. GSA Capital Partners LLP now owns 26,475 shares of the company’s stock valued at $1,247,000 after buying an additional 6,592 shares during the period. Bank of Montreal Can raised its stake in shares of Cambrex Corp. by 31.1% in the fourth quarter. Bank of Montreal Can now owns 31,339 shares of the company’s stock valued at $1,476,000 after buying an additional 7,431 shares during the period. Turner Investments L.P. acquired a new stake in shares of Cambrex Corp. during the fourth quarter valued at about $2,119,000. Finally, Redwood Investments LLC raised its stake in shares of Cambrex Corp. by 28.9% in the fourth quarter. Redwood Investments LLC now owns 45,791 shares of the company’s stock valued at $2,156,000 after buying an additional 10,259 shares during the period.

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.